4th Treg Directed Therapies Summit

Kongressthemen
As Biopharma turn their focus to autoimmune drug development, there has been an explosion of interest and investment into Treg directed therapies. Promising proof-of-concept data and early clinical read outs have fueled further hype, and the industry now looks to demonstrate efficacy.

The 4th Treg Directed Therapies Summit returns to Boston this May, bigger and better than ever before, boasting 2 tracks of unparalleled content to cater to cell-based, and non-cell-based experts alike.

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
Speakers: Richard Ransohof, Co-Founder and CMO Abata and Venture Partner, Third Rock Ventures, Thomas Wickham, CSO, GentiBio, Jonathan Zalevsky, Chief Research and Development Officer, Nektar Therapeutics and more.

https://go.evvnt.com/991160-2?pid=4832

Herr Treg Directed Therapies Summit Team